AlphaCentric Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

AlphaCentric Advisors’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-42,500	Closed	-$1.74M	–	243
2024 Q2	$1.74M	Hold	42,500	–	–	1.28%	20
2024 Q1	$1.8M	Buy	42,500 +17,500	+70%	+$735K	1.08%	29
2023 Q4	$1.06M	Buy	+25,000	New	+$718K	0.71%	54

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

AlphaCentric Advisors's CERE Position: Q3 2024 in Review

AlphaCentric Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 42,500 shares — an estimated $1.74M sold.

AlphaCentric Advisors first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $1.8M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

AlphaCentric Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
AlphaCentric Advisors sold 42,500 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.74M.
AlphaCentric Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
AlphaCentric Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.8M in Q1 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.